Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific

Which one of these medical device makers is better poised for a breakout year?

Better Buy: Medtronic or Boston Scientific?

Medtronic plc (MDT) Management Presents at Jefferies Virtual Healthcare Conference (Transcript)

Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode DUBLIN, June 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 780G system, a small subset of those on the latest system today across nine countries in Europe. Data showed an average overall Time in Range of 76.2% and an overnight Time in Range of 83%, mirroring results from the pivotal trial.

Real-World Data on Over 4,000 Patients Using the Medtronic MiniMed™ 780G System Demonstrate Time in Range Mirroring Pivotal Trial

Cardinal Health

Chubb

Clorox

Northrop Grumman

Without growth, your dividend income stream will lose purchasing power to inflation. April was the best dividend investing month of the year.

4 Dividend Increases Expected In June 2021

These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.

Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe

Data on the Company's Holistic Portfolio Will Include Real-World Data on   MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set DUBLIN, June 1, 2021 /PRNewswire/ --  Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021. Medtronic will showcase clinically meaningful outcomes associated with the company's comprehensive product portfolio and future technologies, as well as customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.

Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes

American Tower

Lowe's

LyondellBasell Industries

Sysco

Universal Corp

This article series covers dividend changes on a weekly basis. A summary table presents relevant data and key statistics of dividend increases.

Dividend Increases: May 22-28, 2021

Titan Medical Inc

Titan Medical Inc (NASDAQ: TMDI) has received $10 million under the second technical milestone under the development and license agreement with Medtronic plc (NYSE: MDT). The development and license agreement provides for developing robotic-assisted surgical technologies for Titan and Medtronic in their respective businesses.

Titan Medical Stock Jumps After Medtronic's $10M Second Milestone Payment

Medtronic plc's (MDT) CEO Geoffrey Martha on Q4 2021 Results - Earnings Call Transcript

Medtronic Plc's (NYSE: MDT) Q4 earnings beat consensus, aided by a recovery in its core business as more people opted for elective procedures that suffered the impact of the COVID-19 pandemic. Q4 adjusted EPS of $1.50 beat the analyst consensus of $1.42, 160% higher than $0.58 from the same period last year.

Medtronic Earnings Double On Procedure Recovery; Hikes Dividend By 9%

The company appeared to turn the corner on COVID-19.

How Medtronic Beat Wall Street Expectations in Its Fiscal Q4

Medtronic's (MDT) fourth-quarter results reflect a strong recovery in terms of elective procedures.

Medtronic's (MDT) Q4 Earnings Beat Estimates, Margins Up

Best Buy

NVIDIA

Pure Storage

Snowflake

Here's a quick look at some earnings reports that were released after markets closed on Wednesday or before Thursday's opening bell.

Earnings Hits and Misses: Best Buy, Medtronic, Nvidia, Pure Storage, Snowflake

Medtronic (MDT) delivered earnings and revenue surprises of 5.63% and 0.55%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates

Shares of Medtronic PLC slipped 0.1% in premarket trading Thursday, after the medical technology and services company reported fiscal fourth-quarter profit and sales that rose above expectations, citing a "strong recovery" in elective procedures, and boosted its dividend by 8.6%, but provided a less than upbeat full-year outlook. Net income for the quarter to April 30 rose to $1.36 billion, or $1.00 a share, from $646 million, or 48 cents a share, in the year-ago period.

Medtronic beats profit and revenue expectations, boosts dividend

Shares of Medtronic (NYSE:MDT) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 158.62% over the past year to $1.50, which beat the estimate of $1.42.

Recap: Medtronic Q4 Earnings

Medtronic earnings and sales topped fiscal Q4 views. The medical technology company's EPS guidance was at best in line.

Medtronic Earnings Top, Guidance So-So With Stock In Buy Zone

DUBLIN, May 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188 billion, an increase of 37 percent as reported and 32 percent on an organic basis, which adjusts for the $241 million benefit of foreign currency translation.

Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase

New No Fingerstick 1  Sensor Integrates with Both the MiniMed 780G System and the Smart InPen System DUBLIN, May 26, 2021 /PRNewswire/ --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark for expanded functionality of the company's InPen™ smart2 insulin pen for multiple daily injections (MDI). The company also announced CE Mark for its Guardian™ 4 sensor3, which requires no fingersticks1 for calibration or diabetes treatment decisions.

Medtronic Secures Two CE Mark Approvals for Guardian 4 Sensor & for InPen MDI Smart Insulin Pen

With the Memorial Day holiday coming up, the flood of earnings reports will be slowing to a trickle until a couple of weeks after the June quarter closes.

Earnings Previews: Best Buy, Medtronic, Nvidia, Pure Storage

Butterfly Network

Microsoft

These attractive AI stocks relate to the healthcare sector, and explore the application of AI in diagnostics, surgery, among others. The post 4 AI Healthcare Stocks Transforming the Medical Industry appeared first on InvestorPlace.

4 AI Healthcare Stocks Transforming the Medical Industry

Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.

Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings

Apple

Garmin

Rising demand for smart medical devices due to their convenience of providing active monitoring of patients makes it wise to look at names like Apple (AAPL), Garmin (GRMN) and Medtronic (MDT).

3 Stocks to Watch on Rising Demand for Smart Medical Devices

Abbott Labs

Ameriprise Financial

Air Products and Chemicals

Cincinnati Financial

Johnson & Johnson

Lumen Technologies

Altria

Philip Morris

Starbucks

Total

Texas Instruments

Visa

Forecasting the income provided from a dividend growth portfolio has proven remarkably accurate, regardless of tweaks to investing philosophy. Long range predictions of an individual stock price is akin to fortune telling, yet in aggregate, the stock market increases with consistency over time.

The Perfect Predictive Power Of Dividends

The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.

News for Medtronic Stock (MDT)